Vagus Nerve Stimulators
Jun 26, 2025
GE HealthCare Receives FDA Approval for Expanded Vizamyl PET Imaging Indications in Alzheimer’s Disease Care; FDA Grants Approval to InspireMD’s CGuard® Prime for Carotid Artery Disease; AngioDynamics Launches RECOVER-AV Trial, Marking Milestone in AlphaVac F18⁸⁵ Development for PE Treatment; Tivic Health Concludes Study Optimizing Non-Invasive Vagus Nerve Stimulation Device for Personalized Therapy; Johnson & Johnson Introduces VOLT™ Plating System and ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM in the U.S.
GE HealthCare Announced that the FDA Approved Expanded Indications for Vizamyl Pet Imaging Agent for Beta Amyloid Detection, Enabling More Precise Care for Alzheimer’s Patients On June 24, 2025, GE HealthCare announced that the U.S. Food and Drug Administration (FDA) approved an updated label for its PET i...
Read More...
Jul 27, 2022
How are Neurostimulation Devices Playing a Vital Role in the Treatment of Chronic Pain?
Around 50 million people in the United States live with—and suffer from—chronic pain. The prevalence of chronic pain has grown significantly over the past few decades due to lifestyle changes, traumatic injury, a rise in critical surgeries, and growth in the overweight or obese population, among serval other underl...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
